NOXAFIL (posaconazole)
OROPHARYNGEAL CANDIDIASIS·+3
SCHERING CORP.
Indication
Prevention of invasive pulmonary aspergillosis
Prevention of invasive pulmonary aspergillosis refers to prophylactic intervention against life-threatening lower respiratory tract infections caused by opportunistic filamentous fungi of the genus *Aspergillus*, most commonly *Aspergillus fumigatus*. Read more about Prevention of invasive pulmonary aspergillosis
31 drugs 29 manufacturers
Drugs that treat it
Common Prevention of invasive pulmonary aspergillosis therapies.
NOXAFIL (posaconazole)
ANTIFUNGALS-SYSTEMIC·OROPHARYNGEAL CANDIDIASIS·+3
Merck Sharp & Dohme
NOXAFIL (posaconazole)
ANTIFUNGALS-SYSTEMIC·PREVENTION OF DISSEMINATED CANDIDIASIS·+2
Merck Sharp & Dohme
NOXAFIL (posaconazole)
ANTIFUNGALS-SYSTEMIC·PREVENTION OF DISSEMINATED CANDIDIASIS·+2
Merck Sharp & Dohme
POSACONAZOLE
ANTIFUNGALS-SYSTEMIC·PREVENTION OF DISSEMINATED CANDIDIASIS·+2
PAR HEALTH USA,
POSACONAZOLE
ANTIFUNGALS-SYSTEMIC·PREVENTION OF DISSEMINATED CANDIDIASIS·+2
Lannett Company
POSACONAZOLE
ANTIFUNGALS-SYSTEMIC·PREVENTION OF DISSEMINATED CANDIDIASIS·+2
Major Pharamceuticals
POSACONAZOLE
ANTIFUNGALS-SYSTEMIC·PREVENTION OF DISSEMINATED CANDIDIASIS·+2
NORTHSTAR RX LL
POSACONAZOLE
ANTIFUNGALS-SYSTEMIC·PREVENTION OF DISSEMINATED CANDIDIASIS·+2
CAMBER PHARMACE
Filter & compare in the drug finder →Opens the drug finder with Prevention of invasive pulmonary aspergillosis preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPrevention of invasive pulmonary aspergillosis refers to prophylactic intervention against life-threatening lower respiratory tract infections caused by opportunistic filamentous fungi of the genus *Aspergillus*, most commonly *Aspergillus fumigatus*.
This strategy targets severely immunocompromised hosts, primarily individuals undergoing hematopoietic stem cell transplantation, solid organ transplant recipients, and patients experiencing prolonged, profound neutropenia from hematologic malignancies or cytotoxic chemotherapy.
Pathophysiologically, the condition is defined by the inhalation of airborne fungal conidia that evade impaired pulmonary host defenses, leading to hyphal germination, tissue necrosis, and angioinvasive destruction within the lung parenchyma.
Prophylaxis aims to prevent the onset of rapid clinical deterioration characterized by fever, pleuritic chest pain, hemoptysis, and potential hematogenous dissemination.
- nih.gov
Prevention of invasive pulmonary aspergillosis refers to prophylactic intervention against life-threatening lower respiratory tract infections caused by opportunistic filamentous fungi of the genus *Aspergillus*, most commonly *Aspergillus fumigatus* This strategy targets severely immunocompromised hosts, primarily individuals undergoing hematopoietic stem cell transplantation, solid organ transplant recipients, and patients experiencing prolonged, profound neutropenia from hematologic malignanc...
- cdc.gov
Prevention of invasive pulmonary aspergillosis refers to prophylactic intervention against life-threatening lower respiratory tract infections caused by opportunistic filamentous fungi of the genus *Aspergillus*, most commonly *Aspergillus fumigatus* This strategy targets severely immunocompromised hosts, primarily individuals undergoing hematopoietic stem cell transplantation, solid organ transplant recipients, and patients experiencing prolonged, profound neutropenia from hematologic malignanc...
- ersnet.org
Prevention of invasive pulmonary aspergillosis refers to prophylactic intervention against life-threatening lower respiratory tract infections caused by opportunistic filamentous fungi of the genus *Aspergillus*, most commonly *Aspergillus fumigatus*
- cdc.gov
This strategy targets severely immunocompromised hosts, primarily individuals undergoing hematopoietic stem cell transplantation, solid organ transplant recipients, and patients experiencing prolonged, profound neutropenia from hematologic malignancies or cytotoxic chemotherapy
- cdc.gov
Prophylaxis aims to prevent the onset of rapid clinical deterioration characterized by fever, pleuritic chest pain, hemoptysis, and potential hematogenous dissemination
Personalize your experience
Follow Prevention of invasive pulmonary aspergillosis and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.